Target-controlled infusion anesthesia (TCIA) is used worldwide to deliver the anesthetic drug propofol for general anesthesia and sedation using small pumps, but has not yet been approved by the FDA. The company’s patent-pending platform represents an enabling technology that demonstrates a compelling pharmacoeconomic model that will open up the North American market to TCIA while at the same time making propofol anesthesia and sedation safer.